Limited Breadth of the Protective Immunity ... - Journal of Virology

Download PDF
3 downloads 0 Views 547KB Size Report
Comment
investigators using similar regimens have reported confficting results. Abimiku et al. (1) showed that macaques immunized with recombinant canarypox vaccines ...
JOURNAL OF VIROLOGY, Jan. 1999, p. 618–630 0022-538X/99/$04.0010 Copyright © 1999, American Society for Microbiology. All Rights Reserved.

Vol. 73, No. 1

Limited Breadth of the Protective Immunity Elicited by Simian Immunodeficiency Virus SIVmne gp160 Vaccines in a Combination Immunization Regimen PATRICIA POLACINO,1 VIRGINIA STALLARD,1† JAMES E. KLANIECKI,2‡ DAVID C. MONTEFIORI,3 ALPHONSE J. LANGLOIS,3 BARBRA A. RICHARDSON,4 JULIE OVERBAUGH,5 WILLIAM R. MORTON,1 RAOUL E. BENVENISTE,6 AND SHIU-LOK HU1,2* Regional Primate Research Center,1 Department of Biostatistics,4 and Department of Microbiology,5 University of Washington, and Bristol-Myers Squibb Pharmaceutical Research Institute,2 Seattle, Washington; Duke University Medical Center, Durham, North Carolina3; and National Cancer Institute, Frederick, Maryland6 Received 23 June 1998/Accepted 29 September 1998

We previously reported that immunization with recombinant simian immunodeficiency virus SIVmne envelope (gp160) vaccines protected macaques against an intravenous challenge by the cloned homologous virus, E11S. In this study, we confirmed this observation and found that the vaccines were effective not only against virus grown on human T-cell lines but also against virus grown on macaque peripheral blood mononuclear cells (PBMC). The breadth of protection, however, was limited. In three experiments, 3 of 10 animals challenged with the parental uncloned SIVmne were completely protected. Of the remaining animals, three were transiently virus positive and four were persistently positive after challenge, as were 10 nonimmunized control animals. Protection was not correlated with levels of serum-neutralizing antibodies against the homologous SIVmne or a related virus, SIVmac251. To gain further insight into the protective mechanism, we analyzed nucleotide sequences in the envelope region of the uncloned challenge virus and compared them with those present in the PBMC of infected animals. The majority (85%) of the uncloned challenge virus was homologous to the molecular clone from which the vaccines were made (E11S type). The remaining 15% contained conserved changes in the V1 region (variant types). Control animals infected with this uncloned virus had different proportions of the two genotypes, whereas three of four immunized but persistently infected animals had >99% of the variant types early after infection. These results indicate that the protective immunity elicited by recombinant gp160 vaccines is restricted primarily to the homologous virus and suggest the possibility that immune responses directed to the V1 region of the envelope protein play a role in protection. results. Abimiku et al. (1) showed that macaques immunized with recombinant canarypox vaccines and boosted with subunit HIV-1 proteins were partially protected against infection by HIV-2, a divergent albeit nonpathogenic virus. Hirsch et al. (28) showed that immunization with a modified vaccinia virusbased trivalent SIV vaccine followed with inactivated SIV failed to protect against infection by a more pathogenic challenge virus, SIVsmE660, but was able to reduce the virus load, resulting in prolonged disease-free survival in infected macaques. On the other hand, Giavedoni et al. (25) and Daniel et al. (19) showed that combination immunization regimens with recombinant vaccinia virus priming and subunit antigen boosting resulted only in reduction of the viral load in a minority of animals challenged with a highly pathogenic virus, SIVmac251, with no apparent benefit in disease outcome. Direct comparison of these studies, however, is hampered by the divergent nature of the challenge viruses and by the different vectors, immunogens, and immunization regimens used. To study the protective efficacy of the combination immunization strategy more systematically, we first investigated the limits of the protective immunity elicited by the envelope antigens alone in the SIVmne model, where complete protection was achieved against a pathogenic cloned virus, E11S. In this communication, we demonstrate that the protective immunity elicited by recombinant gp160 vaccines was restricted primarily to the homologous cloned virus. Only partial protection against the uncloned virus SIVmne was achieved. Analyses of SIVspecific antibodies failed to reveal any correlation between protection and serum neutralization. However, analysis of

The surface antigens of human immunodeficiency virus type 1 (HIV-1) have been the primary targets in attempts to develop an AIDS vaccine in the last decade (24, 54). The efficacy of envelope-based vaccines has been demonstrated largely in the chimpanzee model against tissue culture-adapted viruses such as HIV-1 IIIB (10, 11, 15, 26, 43, 57) and SF2 (14, 22). Infection by these virus isolates is generally self-limiting and does not lead to AIDS-like diseases. Furthermore, the scarcity of these animals and the expenses involved limit the value of this model for the evaluation of multiple vaccine approaches under different conditions. To circumvent these limitations, a number of investigators have used macaque models with simian immunodeficiency viruses (SIV) that vary in the rapidity with which they induce CD41 cell depletion or death (33, 52). Using a pathogenic cloned virus, SIVmne E11S, we demonstrated complete protection against the homologous virus with gp160 vaccines in a combination immunization regimen that consisted of recombinant vaccinia virus for priming and subunit protein for boosting (30, 32). However, the protective efficacy of this immunization approach remains controversial, since a number of investigators using similar regimens have reported conflicting * Corresponding author. Present address: Department of Pharmaceutics and Regional Primate Research Center, Box 357331, University of Washington, Seattle, WA 98195. Phone: (206) 616-9764. Fax: (206) 543-3204. E-mail: [email protected]. † Present address: Sequim, WA 98382. ‡ Present address: Corixa Corp., Seattle, WA 98104. 618

VOL. 73, 1999

PROTECTION BY SIVmne gp160 VACCINES

“breakthrough” viruses in infected animals indicates that protection against SIV infection may be attributable in part to immune responses directed to the V1 hypervariable region within the envelope antigen. MATERIALS AND METHODS Immunogens and immunization regimen. Recombinant vaccinia virus vacgp160 (v-SE5) contains the coding sequence of the full-length gp160 of SIVmne molecular clone 8 in a New York City Board of Health strain (v-NY) of vaccinia virus (30, 32). Molecular clone 8 is a derivative of the SIVmne single-cell clone E11S and has an identical env sequence to the parental virus, E11S (17, 48a). V-SE5 was plaque purified and propagated on African green monkey kidney (BSC-40) cells (32). Nineteen cynomolgus macaques (Macaca fascicularis) were each inoculated with 108 PFU of the recombinant virus by skin scarification at two or three sites along opposite sides of the midline of the back. Booster immunizations were done by intramuscular injections at 2 to 3, 10 to 18, and 12 to 26 months with gp160 produced either in recombinant baculovirus-infected insect cells (experiment 1) (31) or in BSC-40 cells infected with recombinant vaccinia virus (experiments 2 and 3). Similar to their HIV-1 counterparts (13, 38), SIVmne gp160 produced in these systems are glycosylated, have an apparent molecular mass of 160 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and bind to recombinant human CD4 (data not shown). Size exclusion chromatography has shown that the majority of the gp160 produced in the vaccinia virus expression system are oligomeric, mostly trimeric or tetrameric (data not shown). Each booster dose contained 250 mg of total protein (corresponding to approximately 125 mg of gp160) formulated in Freund’s incomplete adjuvant. Challenge virus and conditions. SIVmne was isolated from a pigtailed macaque (M. nemestrina) with lymphoma and was propagated on HuT 78 cells (6). E11S is a single-cell clone of SIVmne-infected HuT 78 cells that produced large amounts of envelope glycoproteins (8). Challenge was performed 4 weeks after the last immunization by an intravenous injection. Challenge with SIVmne clone E11S was performed with 10 to 100 animal infectious doses (AID) of virus grown on either HuT 78 cells or macaque peripheral blood mononuclear cells (PBMC). Challenge with uncloned SIVmne was done with 10 to 100 AID (experiment 1) or 2-20 AID (experiments 2 and 3) of virus grown on HuT 78 cells. Some of the animals protected from the E11S challenge were held for 1 to 2 years to confirm their virus-negative status before they were given further booster doses with gp160 and rechallenged 4 weeks later with uncloned SIVmne. Blood samples were collected on the day of challenge, at 2, 4, 6, and 8 weeks after challenge, and monthly thereafter. Plasma and serum samples were collected and stored until used at 270 and 220°C, respectively. Lymph node biopsy specimens were obtained at the indicated times after challenge and were frozen at 270°C for DNA analysis or fixed for histological examinations. The animals were housed in the Washington Regional Primate Research Center and were under the care of licensed veterinarians. Euthanasia was performed on the basis of the following criteria: (i) AIDS; (ii) termination of the experiment; or (iii) unrelated cause. Euthanasia is considered to be AIDS related if the animal exhibits CD41 cell depletion in the peripheral blood and two or more of the following conditions: wasting, unsupportable diarrhea, opportunistic infections, proliferative diseases (e.g., lymphoma), and abnormal hematological profile (e.g., anemia, leukopenia, or thrombocytopenia). Virus isolation. PBMC were isolated over Histopaque-1077 (Sigma Chemical Co., St. Louis, Mo.) as described previously (7, 9). Briefly, 4 3 106 PBMC were cocultivated with 5 3 106 AA-2CL5 cells, and cultures were maintained for 8 to 9 weeks. Virus was detected by reverse transcriptase assays performed as described previously (9). A positive value means positive results in reverse transcriptase assays, and a negative value means no reverse transcriptase activity detected after 8 to 9 weeks of cocultivation. Serum neutralization assays. Neutralizing antibodies against uncloned SIVmne and SIVmne clone E11S were measured in CEM-X174 cells by methods similar to those described by Montefiori et al. (46). The uncloned SIVmne used for neutralization studies was grown on HuT 78 cells and was identical to the challenge stock but was prepared at different times. The E11S clone used for neutralization assays was grown on macaque PBMC after initial isolation and propagation in HuT 78 cells (6). It was derived from the same stock as the challenge virus but grown on PBMC from a different M. fascicularis animal. Neutralization of a related but heterologous virus, SIVmac251, was measured in HuT 78 cells as described by Langlois et al. (40). Twofold serum dilutions (heat inactivated at 56°C for 30 min) were made in 96-well plates. The neutralization titer is expressed as the reciprocal serum dilution that inhibits 50% of SIVmneinduced cytopathic effect in CEM-X174 cells or 90% of the syncytium formation by SIVmac251-infected Hut-78 cells. ELISA. SIV-specific antibodies were measured by an enzyme-linked immunosorbent assay (ELISA) as described previously (29), except that gradientpurified and disrupted whole SIVmne clone E11S virion was used as the antigen in ELISA. End-point titers were determined as the reciprocal of the highest serum dilution that resulted in an optical density reading threefold greater than that obtained with negative control sera.

619

Nested PCR analysis. PBMC were isolated from EDTA-treated blood by Hypaque-Ficoll gradient centrifugation, and nucleic acid was extracted by standard techniques. A 1-mg sample of total nucleic acid was used as a template for a two-step amplification by PCR with a nested set of oligonucleotide primers specific for the envelope regions. The conditions for the first and second rounds of amplification were as described previously (30). The final amplified fragment was approximately 642 bp. Amplified products were resolved by agarose gel electrophoresis and visualized by ethidium bromide staining. Results for a subset of samples were also confirmed by PCR with primers from env and long terminal repeat (LTR)-gag regions. Semiquantitative PCR analysis of the proviral DNA load. The amount of proviral DNA in PBMC was measured by PCR with radiolabeled primer incorporation for quantification (50) and was expressed as the number of copies of proviral genome detected per million PBMC. Briefly, 1 mg of DNA from each sample was amplified in a PCR mixture that contained 0.2 mM each primer, 200 mM each deoxynucleoside triphosphate, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, and 1.0 U of Taq polymerase (Perkin-Elmer Cetus, Branchburg, N.J.) in a volume of 50 ml. The reaction was subjected to 30 cycles of denaturation for 1 min at 94°C, annealing for 2 min at 60°C, and elongation for 3 min at 70°C. The oligonucleotide primers used were derived from the nucleotide sequence of SIVmne (GenBank accession no. M32741 [27]). They consist of a primer pair specific for the env region, env10 (7191 to 7211 [sense]) and env12 (7541 to 7561 [antisense]), and a primer pair specific for the LTR-gag region, S1 (228 to 251 [sense]) and S8 (536 to 559 [antisense]). The amplified products for the env and the LTR sequences are 370 and 330 bp, respectively. One oligonucleotide of each complementary pair was 59-end labeled with [32P]ATP by the use of polynucleotide kinase (New England Biolabs, Inc., Beverly, Mass.). The 32Plabeled PCR products obtained by amplification were analyzed by electrophoresis on 8% nondenaturing polyacrylamide gels and quantified by autoradiography by phosphorimager analysis (50). The amount of SIV DNA was determined by using a standard curve generated with known quantities of a plasmid clone of E11S. RT-QC-PCR determination of plasma viral RNA. Plasma viral RNA was prepared as described by Watson et al. (56). The viral RNA samples were serially diluted in a 96-well PCR microplate into a reaction buffer containing a fixed copy number of a competitor RNA containing an internal deletion. The template and the competitor were subjected to reverse transcription (RT) followed by quantitative competitive PCR (QC-PCR). The primers used are from the SIVmne gag sequence: 59 primer (5G) from nucleotides 675 to 698 (AAAGCCTGTTGGA GAACAAAGAAG) and 39 primer (3Diii) from nucleotides 993 to 1011 (AAT TTTACCCAGGCATTTA). The internal RNA control contains a deletion of 82 bp, which enables products amplified from the viral (336-bp) and the control (254-bp) templates to be distinguished. The conditions for the RT reaction and QC-PCR were as described by Watson et al. (56). Sequencing of the env hypervariable regions of uncloned SIVmne. Infected HuT 78 cells from which the uncloned SIVmne challenge stock was derived were used as the source in a determination of viral genomic sequence and complexity. The region in env encompassing the hypervariable regions V1 to V5 was amplified by PCR and subcloned into M13 vectors for sequence analysis. The method was based on that described by Overbaugh et al. (49). Briefly, genomic DNA was isolated from infected cells and the V1 to V5 region in the SIV env gene was amplified by two rounds of PCR with nested sets of primers: for the first round, Env1 (6346 to 6367, 59-ATAGGTACCCTCTTTGAGACC TCAATAAA-39 [sense]) and Env8 (7575 to 7594, 59-ATAGAATTCCCAATTGGAGTG ATCT CTAC-39 [antisense]), and for the second round, Env7 (6364 to 6382, 59-GAC GGTACCTAAAGCCTTGTGTAAAATTA-39 [sense]) and Env4 (7524 to 7544, 59-GAATTCAGTTCTGCCACCTCTGCACT-39 [antisense]). The inside primers were designed to contain restriction sites at the 59 ends for subsequent cloning into M13 vectors for sequence analysis. To minimize possible bias introduced by PCR amplification, we performed six independent amplifications for each DNA sample and generated three or four subclones for each amplified DNA sample for sequence analysis. Analysis of the proviral DNA sequence in PBMC or lymph node cells from animals infected with uncloned SIVmne. Proviral DNA sequences in infected macaques were analyzed by one or more of the following methods. The first was nucleotide sequencing. The same method used for the analysis of uncloned SIVmne virus stock was used to analyze proviral sequences present in the PBMC or lymph node cells from infected animals. The second was PCR amplification with radiolabeled primers. Results from nucleotide sequence analysis indicate that the majority of the sequence variations in the env gene of the uncloned virus are present in the V1 region. A total of 85% of the amplified V1 sequence in the challenge stock is identical to that of E11S (E11S type), while the remaining 15% shares a consensus sequence in V1 that is different from E11S (variant types). Based on this information, we designed two oligonucleotide probes (nucleotides 6471 to 6499), one specific for the E11S-like sequence (E11Sp, 59-TTTATTGC CTCTGCTTTTGTTGGTATTGC-39 [antisense]) and the other for the varianttype sequences (Variantp, 59-TCTATTTTCTTTGTTGTTGGTTTTGGTGT-39 [antisense]). The E11Sp probe hybridizes with the proviral cDNA of E11S and uncloned SIVmne, while the Variantp probe hybridizes only with the latter. With primers specific for the E11S or the variant type sequences, we amplified V1 sequences in the PBMC or the lymph node cells of infected macaques. A radiolabeled primer specific for the V1 region (Env71, 6097 to 6120, 59-TTAT

620

POLACINO ET AL.

CGCCATCTTG TTTCTAAGTG 39 [sense]) was used in combination with the antisense primers specific for the E11S or variant sequences. The amplified product, which was 397 bp, was resolved by electrophoresis on 8% nondenaturing polyacrylamide gels, and the relative abundance of the E11S-type and the variant-type sequences was determined by autoradiography using phosphorimager analysis as described above. For each PCR amplification, DNA from E11Sinfected and uncloned SIVmne-infected cells were used as controls. The third method was the heteroduplex mobility assay. Heteroduplex formation conditions were used as described by Delwart et al. (20). Briefly, DNA from infected cells (1 mg per reaction) was amplified by nested PCR. The primers for the first round were Env1 and Env 8, and those for the second round were Env7 and Env14 (6740 to 6757, 59-CTAATAGCATCCCAATAA-39 [antisense]). Of the 50-ml first round reaction mixture, 2 ml was used for the second-round amplification. The final product is 394 bp and spans the V1 to V2 region. For heteroduplex formation, we combined 4.5 ml of the PCR products amplified from the proviral DNA of E11S-infected cells and an equal volume of PCR product from the test DNA sample with 1 ml of 103 annealing buffer (1 M NaCl, 100 mM Tris-HCl [pH 7.8], 20 mM EDTA). DNA in the mixture was denatured at 94°C for 2 min and annealed by cooling on ice as described by Delwart et al. (20). Reannealed products were resolved by electrophoresis on a 5% polyacrylamide gel and stained with ethidium bromide. Lymphocyte subset analysis. Cell surface immunofluorescence was quantified with a FACScan flow cytometer and Lysis II software (Becton Dickinson Immunocytometry Systems, San Jose, Calif.). Lymphocyte subsets (CD4, CD8, CD2, and CD20) of whole heparinized blood samples were evaluated by conventional methods. Statistical analysis. Differences in proportions were tested by Pearson’s chisquare test or Fisher’s exact test. Differences between medians of continuous variables were tested by the Mann-Whitney U test.

RESULTS Immunization regimen and outcome of challenge. The protective efficacy of gp160 vaccines was evaluated in a total of 19 macaques in three separate experiments (Table 1). All animals in the experimental group received one or two inoculations of recombinant vaccinia virus expressing the gp160 gene of SIVmne clone 8 (GenBank accession number M32741 [27]) followed by two or three booster immunizations with subunit gp160 prepared either from recombinant baculovirus-infected insect cells (Table 1, experiment 1) or from recombinant vaccinia virus-infected mammalian cells (Table 1, experiments 2 and 3). In experiments 1 and 3, the animals were challenged first with homologous virus E11S clone grown either on the HuT 78 cell line or on macaque PBMC. The protected animals were then rechallenged with uncloned virus SIVmne. In experiment 2, the animals were challenged in parallel with the cloned or uncloned virus. All challenges were performed by intravenous injection as described. Infection was monitored by nested PCR, virus isolation by coculture, measurement of the anamnestic response, and measurement of seroconversion to nonvaccine antigens. The outcome of the challenge is summarized in Table 2. We previously reported that immunization with gp160 in a poxvirus-priming plus subunit protein-boosting regimen protected four of four macaques from an intravenous challenge by the homologous virus clone E11S (30). The same immunization regimen also protected two of two animals that were previously inoculated with an unrelated vaccinia virus (32). Updated data on these six animals are summarized in Table 2 (experiment 1). To exclude the possibility that protection against E11S was due to cross-reactive immune responses directed to human cell antigens present in the challenge virus, we immunized six animals in experiment 2 and challenged four (macaques 90114, 90090, 90108, and 91074) with E11S grown on macaque PBMC and two (macaques 89153 and 90079) with the same virus grown on HuT 78 cells. All but one were completely protected. The only immunized animal (macaque 90114) that became infected with the virus grown in PBMC had a reduced level of proviral DNA detectable only at week 2 after challenge. This observation was repeated in experiment 3, in which three of four immunized macaques challenged with

J. VIROL. TABLE 1. Summary of the animals used and the immunization and challenge conditions Challenge virus

E11S clone

Uncloned SIVmne

Group

Animals used in: Expt 1

Expt 2

Expt 3

Control

88033 89079 89134 89152 87215 90125

89144 91419 92175c 92176c 93025c

91077c 91078c M92387c 93057c

Immunizeda

87201 87210 87217 87221 85180b 86180b

89153 90079 90114c 90090c 90108c 91074c

J90304c 91272c 91250c 91263c

Control

91319 91320 91323 91324

92170 92179 93032

91064 91070 92168

Immunized

87201d 87210d 87217d 87221d

90073 90078 90094

J90304d 91250d 91263d

a In experiment 1, recombinant vaccinia virus was given at weeks 0 and 10 and subunit gp160 was given at weeks 62 and 70. Subunit gp160 was produced in recombinant baculovirus-infected insect cells (31). In experiment 2, recombinant vaccinia virus was given at week 0 and subunit gp160 was given at weeks 10, 41, and 47 for animals 89153 and 90079 and at weeks 10, 84, and 89 for the others. The gp160 used in this experiment was produced in recombinant vaccinia virusinfected African green monkey kidney cells (38). In experiment 3, recombinant vaccinia virus was given at week 0 and subunit gp160 (from the same source as in experiment 2) was given at weeks 12, 74, and 105. b Animals were previously immunized against an irrelevant recombinant vaccinia virus (32). c Challenge virus was grown in macaque PBMC. d Animals previously protected against E11S challenge were monitored for 1 to 2 years before being given booster doses of gp160 and were rechallenged 4 weeks later with uncloned SIVmne.

the virus grown on PBMC were completely protected and one animal (macaque 91272) had a reduced level of proviral DNA only at week 2 following challenge (Fig. 1). Therefore, protection against E11S was not dependent on the origin of the cell substrate used to prepare the challenge virus stocks. In total, 14 of the 16 animals immunized with gp160 were completely protected against SIVmne E11S; the other two animals showed transiently detectable virus only early after infection (Table 3). In contrast, eight of eight and six of seven control animals challenged with E11S grown, respectively, in HuT 78 or macaque PBMC became persistently infected. Only one control animal (monkey 92175) resisted infection. Protection among immunized animals was highly significant (Table 3, 14 of 16 versus 1 of 15; P , 0.001). To examine the breadth of protective immunity, we gave booster doses to animals that had been completely protected against the E11S challenge in experiments 1 and 3 and rechallenged them intravenously with the uncloned virus SIVmne grown on HuT 78 cells. These animals were virus negative by all criteria at all times tested for 1 or 2 years after the first challenge. In addition, in experiment 2, we used three immunized animals that had never been exposed to SIV and challenged them with the uncloned virus, in parallel with similarly immunized animals challenged at the same time with the

VOL. 73, 1999

PROTECTION BY SIVmne gp160 VACCINES

621

TABLE 2. Virus isolation and nested PCR analysis of PBMC and lymph node cells from macaques after challenge with E11S or uncloned SIVmne Challenge virus

Result of analysisa

Macaque

Expt 1 Timeb (wk) E11S Control 88033 89079 89134 89152 87215 90125 Immunized 87201 87210 87217 87221 85180 86180 Timeb (wk) Uncloned Control 91319 91320 91323 91324 Immunized 87201 87210 87217 87221 Expt 2 Timeb (wk) E11S Control 89144 91419 92175 92176 93025 Immunized 89153 90079 90114 90090 90108 91074 Timeb (wk) Uncloned Control 92170 92179 93032 Immunized 90073 90078 90094 Expt. 3 Timeb (wk) E11S Control 91077 91078 M92387 93057 Immunized J90304 91272 91250 91263 Timeb (wk) Uncloned Control 91064 91070 92168 Immunized J90304 91250 91263

2

4

6

11

17

20

39

43

57

100

110

135

200

2/2 1/1 1/1 1/1 2/2 2/2

1/1 1/1 1/1 1/1 1/1 NT

1/1 1/1 1/1 1/1 1/1 1/1

2/1 1/1 1/1 1/1 1/1 2/1

2/1 2/1 1/1 1/1 NT NT

1/1 2/2 2/1 1/1 1/1 1/1

2/NT 2/NT 1/NT 1/NT 2/NT 1/NT

2/2/1 NT NT 1/1/1 2/2 2/2

2/NT 2/NT 1/NT 1/NT 2/2 1/1

NT NT NT NT 2/2 1/1

NT NT A A 2/2 1/NT

A A 2/2 A

E

2/2 2/2 2/2 2/2 2/2 2/2

2/2 2/2 2/2 2/2 2/2 2/2

2/2 2/2 2/2 2/2 2/2 2/2

2/2 2/2 2/2 2/2 2/2 2/2

2/2 2/2 2/2 2/2 2/2 2/2

2/2 2/2 2/2 2/2 2/2 2/2

2/2 2/2 2/2 2/2 2/2 2/NT

2/2/2 2/2/2 2/2/2 2/2/2 2/2 2/2

2/NT 2/NT 2/NT 2/NT 2/2 2/2

R R R R 2/2 2/2

2/2 2/2

2/2 2/2

E E

2

4

8

28

53

66

80

130

186

215

230

252

280

1/1 1/1 1/1 1/1

1/1 1/1 1/1 1/1

1/1 1/1 2/1 1/1

A 1/1 2/1 2/1

A 2/1 2/1

2/1 1/1

2/2 1/1

2/1 1/1

2/2 1/1

2/1 1/1

2/1 1/1

2/NT U

E

1/1 1/2 2/2 1/1

1/1 2/2 2/2 1/1

1/1 2/1 2/2 1/1

1/1 2/2 2/2 A

2/1 2/2 2/2

1/NT 2/2 2/2

1/NT 2/NT 2/NT

A 2/2 2/2

2/2 2/2

2/2 2/2

E E

2

4

8

24

34

66

75

100

110

123

130

145

200

228

1/1 1/1 2/2 1/1 1/1

2/1 1/1 2/2 1/1 1/1

2/1 1/1 2/2 1/1 1/1

2/1 1/1 2/2 2/1 2/1

2/1 1/1 2/2 2/1 2/2

1/1 1/1 2/2 1/1 2/2

1/NT 1/NT 2/2 1/1 2/2

2/1 A 2/2 1/1 2/2

1/NT

A

R 1/1 2/2

NT 2/2

A 2/2

2/NT

2/2

E

2/2 2/2 2/1 2/2 2/2 2/2

2/2 2/2 2/2 2/2 2/2 2/2

2/2 2/2 2/2 2/2 2/2 2/2

2/2 2/2 2/2 2/2 2/2 2/2

2/2 2/2 2/2 2/2 2/2 2/2

2/2 2/2 2/2 2/2 2/2 2/2

2/NT 2/NT 2/2 2/2 2/2 2/2

2/2 2/2 2/2 NT/2 NT/2 NT/2

2/2 2/2 2/2 R R R

2/NT 2/NT 2/2

2/NT 2/NT 2/2

2/NT 2/NT 2/2

E E 2/2

2/2

2

4

6

8

24

34

58

66

100

115

130

144

228

230

1/1 1/1 1/1

1/1 1/1 1/1

1/1 1/1 1/1

1/1 2/2 1/1

1/1 2/2 1/1

1/1 2/2 1/1

1/1 2/2 1/1

A 2/2 1/1

2/2 1/1

2/2 A

2/2

2/2

E

2/2 2/2 1/1

2/2 1/1 1/1

2/2 1/1 1/1

2/2 2/1 1/1

2/2 2/2 1/1

2/2 2/2 2/1

2/2 2/2 2/1

2/2 2/2 2/1

2/2 2/2 2/1

2/2 2/2 2/1

2/NT 2/NT 2/NT

2/2 2/2 2/1

2/2 2/2 2/2

2/2 E E

2

4

8

12

16

20

36

44

74

83

91

107

172

191

196

1/1 1/1 1/1 1/1

1/1 1/1 1/1 1/1

1/1 1/1 1/1 1/1

2/1 2/1 1/1/1 1/1

2/1/1 2/1 1/1 1/1/1

2/1 2/1/1 1/1 2/1

2/1 2/2 1/1 2/1

2/1 1/1 1/1 2/1

2/1 2/1 1/NT 2/NT

2/1 2/2 1/1 2/2

2/2 2/2 1/1 NT/?

2/1 2/1 1/1 2/2

2/2 2/2 A 2/2

2/1 2/2

E E

2/2 2/1 2/2 2/2

2/2 1/2 2/2 2/2

2/2 2/2 2/2 2/2

2/2 2/2 2/2 2/2

2/2 2/2/1 2/2 2/2

2/2/2 2/2/1 2/2/2 2/2/2

2/2 1/2 2/2 2/2

R 2/1 R R

1/1

1/1

1/1

A

2

6

8

12

16

20

32

48

56

64

87

118

126

136

162

1/1 1/1 1/1

1/1 1/1 1/1

1/1/1 NT/1/1 1/1/1

1/1 1/1 2/1

1/1 1/1 2/1

1/1 1/1 2/1

1/1 2/1 1/1

1/1 1/1 2/1

1/1 1/1 2/1

1/1 1/1 2/1

1/1 1/1 2/2

1/1 1/1 1/1

1/1 1/NT 2/2

A 1/1 1/1

A 2/2

1/1 1/2 2/2

1/1/1 2/1/1 2/2/2

1/1 2/2 2/2

2/1 2/1 2/2

1/1 2/2 2/2

2/1 2/2 2/1

1/1 2/2 2/2

1/1 2/2 2/2

1/1 2/2 ?

1/1 2/2 2/2

1/1 2/2 2/2

1/1 2/2 ?

2/1 2/2 2/2

1/1 2/2 2/2

2/1 2/2 2/2

E

a Symbols within each column denote positive (1) or negative (2) results in PBMC virus isolation/PBMC PCR/lymph node PCR. R, reassigned to be rechallenged with uncloned SIVmne; A, AIDS-related euthanasia; E; elective euthanasia; U: unrelated death; NT, not tested; ?, results inconclusive. b Time after challenge.

622

POLACINO ET AL.

cloned virus. Partial protection was observed in all three experiments. Of the four immunized animals in experiment 1, two became persistently virus positive by nested-set PCR analysis, one was only transiently positive at week 8, and one was completely negative after challenge. In both experiments 2 and 3, one animal was persistently virus positive (macaques 90094 and J90304, respectively), one was transiently positive (macaques 90078 and 91250, respectively) and one was completely protected (macaques 90073 and 91263, respectively) (Table 1 and Fig. 1). In total, 3 of 10 immunized animals were completely protected, another 3 showed transiently detectable virus at reduced levels, and 4 were indistinguishable from the 10 persistently infected control animals (Table 3). Although immunization failed to confer complete protection against uncloned virus (3 of 10 animals versus 0 of 10, P 5 0.2), a statistically significant proportion of immunized animals showed reduced or no detectable virus after challenge (6 of 10 of the immunized animals versus 0 of 10 of the controls, P 5 0.005). There was no significant difference in the challenge outcome between the seven animals that were challenged with E11S previously and the three that received the uncloned virus challenge for the first time. SIV-specific responses in immunized animals. SIV-specific antibody responses were monitored throughout the study by ELISA with disrupted whole virions, by immunoblotting (data not shown), and by serum neutralization assays against the challenge virus and a heterologous SIV strain before and after the challenge inoculation. As observed previously, all animals developed low levels of SIV-specific antibody response, which increased 10- to 30-fold after the first subunit protein immunization (reference 30 and data not shown). By the time of

J. VIROL. TABLE 3. Summary of challenge outcome

Animals

No. of animals protected/total no. (%) E11S clone

Uncloned SIVmne

Immunized Protected Transiently virus positive Persistently virus positive

14/16 (88) 2/16 (12) 0/16 (0)

3/10 (30) 3/10 (30) 4/10 (40)

Controls Uninfected Persistently virus positive P

1/15 (7) 14/15 (93) ,0.001b

0/10 (0) 10/10 (100) 0.005c

Pa

0.009 0.03 0.01 1.0 1.0

a P values in this column are based on comparisons between the outcomes of challenge with E11S clone and uncloned SIVmne. b P value for the difference between the number of animals in the immunized group protected against E11S and that in the control group (14 of 16 and 1 of 15, respectively). c P value for the difference between the number of animals in the immunized group showing protection or transient viremia after uncloned SIVmne challenge and that in the control group (6 of 10 and 0 of 10, respectively).

challenge, all the immunized animals developed SIV-specific antibodies, although the titers varied (Fig. 2). The sera of these animals were also able to neutralize a heterologous virus, SIVmac251, passaged in HuT 78 cells. However, some of the immunized animals had only low levels of neutralizing antibodies against the challenge virus SIVmne E11S. As shown in Fig. 2, there was no correlation between the challenge outcome in

FIG. 1. PBMC proviral load in macaques after challenge with SIVmne E11S clone (top) or uncloned SIVmne (bottom). Proviral load was determined by PCR analysis with radiolabeled primer incorporation, as described in Materials and Methods. Values are expressed as copies of proviral genome per 106 PBMC. Proviral DNA was measured by using an external E11S DNA standard of known quantities.

VOL. 73, 1999

PROTECTION BY SIVmne gp160 VACCINES

623

FIG. 2. SIV-specific antibody responses in immunized macaques. Sera collected on the day of challenge were analyzed for neutralizing activities against the homologous challenge virus (E11S or uncloned SIVmne) and a heterologous virus SIVmac251. Neutralizing titers are expressed as the reciprocal serum dilutions that resulted in .90% reduction of syncytium formation by SIVmac251 on HuT 78 cells (center) or .50% cytopathicity of E11S or uncloned SIVmne infection in CEMx174 cells (left). Serum reactivity with disrupted SIVmne E11S virion proteins was analyzed by ELISA, and the results are expressed as end-point titers (right). (a) Animals challenged with SIVmne E11S. (b) Animals challenged with uncloned SIVmne. Solid symbols denote protected animals; open symbols denote the persistently infected ones; crossed symbols denote the transiently viremic ones. The upper and lower dotted lines represent, respectively, the titers of positive and negative control serum samples in each assay. Nab, neutralizing antibody.

these animals and their SIV-specific antibody titer at the time of challenge as measured by the methods described. All animals showed declining levels of SIV-specific antibody titers after the E11S challenge (Fig. 3 and data not shown), including the two animals (macaques 90114 and 91272) that showed transiently detectable proviral cDNA in their PBMC after challenge. After about 6 months, antibody titers in all animals generally declined about 10- to 20-fold and remained at this level thereafter (with the exception of animal 91272, as noted below). After the booster immunization administered 1 to 2 years after the E11S challenge, SIV-specific antibody titers increased to their previous levels (Fig. 3 and data not shown), with the exception of the unchanged titer in animal 87201. At the time of challenge with uncloned SIVmne, all immunized animals (including animals that were never previously challenged) had measurable titers of SIV-specific antibodies that neutralized SIVmac251 (Fig. 2). However, some of the animals had only low levels of neutralizing antibodies against the challenge virus (uncloned SIVmne). Again, no correlation was evident between the level of SIV-specific antibody response and the challenge outcome (Fig. 2). After they were challenged with the uncloned virus, all persistently infected animals (macaques 87201, 87221, 90094, and J90304) showed significant increases in their SIV-specific antibody titers, which were maintained at levels similar to those in control animals (Fig. 3). All the protected animals (ma-

caques 87217, 90073, and 91263) showed no anamnestic response as measured by ELISA (Fig. 3) and neutralizing-antibody assays (data not shown). Transiently viremic animals had more varied responses. The antibody titer in macaque 87210 declined initially but increased significantly after 6 months (Fig. 3A and see below). Titers in macaque 90078 increased initially but declined subsequently and remained at prechallenge levels for .1 year (Fig. 3B). Macaque 91250 showed no anamnestic response, and, as in protected animals, its antibody titer declined 10-fold within 6 months after challenge (Fig. 3C). Analysis of viral sequences recovered from infected animals. To gain further insight into the basis for the success or failure of the gp160 immunizations, we examined proviral sequences recovered from infected animals after the uncloned virus challenge and compared them with sequences present in the inoculum. We first analyzed proviral sequences in HuT 78 cells infected with the same uncloned SIVmne virus stock used for the challenge studies. We used nested sets of primers in a two-step PCR to amplify env sequences encompassing the entire region containing V1 to V5. Amplified fragments were subcloned in M13 vectors for nucleotide sequence analysis. Three or four subclones from each of six independent amplification reactions were used to minimize any potential bias introduced by the amplification and cloning procedures. Of 20 clones analyzed, 12 had V1 to V5 sequences identical to that of SIVmne biological clone E11S or its derivative molecular clone

624

POLACINO ET AL.

J. VIROL.

FIG. 3. SIV-specific antibody responses in immunized and control macaques after challenge. Dilutions of macaque sera collected at the indicated times were incubated with disrupted, gradient-purified SIVmne virion proteins immobilized on microtiter plates. End-point titers were defined as the reciprocal of the highest

VOL. 73, 1999

PROTECTION BY SIVmne gp160 VACCINES

625

dilution that gave an optical absorbance value at least threefold higher than the average values obtained with SIV-negative macaque sera. (A) Experiment 1. (B) Experiment 2. (C) Experiment 3. For each panel, the top row gives results for animals challenged with SIVmne E11S and the bottom row gives results for animals challenged with uncloned SIVmne.

8 (8). Five clones had one or more nucleotide substitutions, resulting in two nonsynonymous amino acid changes in one clone and a single amino acid change in two others. All were unique within the V1 and V2 regions. Of the remaining three clones, all had multiple amino acid changes clustered in the V1 region. Although there were one or two amino acid changes unique to each clone outside this region, all three clones had the same sequence (TPKPTTTKKIE) distinct from that of E11S or molecular clone 8 (AI-PTKAEAIK, corresponding to amino acid residues 134 to 143) (Table 4). Using 32P-labeled oligonucleotide primers specific for these distinct sequences, we amplified the V1 env fragments directly from the proviral genomes of the uncloned viruses. Although the E11S-specific primer amplified both E11S and uncloned viral sequences, the variant-specific primer amplified only the latter (Fig. 4A). Quantification of the amount of 32P label hybridized indicated that 85% of the fragments amplified from the uncloned virus had E11S-like sequences while the remaining 15% were of the variant type, in agreement with results of the sequence analysis of individual clones. Results from heteroduplex mobility anal-

yses also confirmed the relative complexity of these viral stocks (Fig. 4B). Nucleotide sequencing, heteroduplex mobility analyses, and specific labeled-primer amplification analyses were used to identify and quantify the proportion of E11S-like and variantlike sequences present in the PBMC and lymph nodes of macaques infected with uncloned SIVmne. Because viral genotypes evolve in infected animals, we focused our analyses on the earliest samples from which we were able to detect at least 50 copies of viral sequences per microgram of total DNA (approximately 2 3 105 cells). For most animals, we used samples collected 2 weeks after infection. For others, which had low or transiently detectable viral loads, we used samples collected at 4 or 6 weeks. The results of nucleotide sequence and labeled-primer amplification analyses are concordant and are summarized in Table 5. The majority of control (nonimmunized) macaques had mixtures of E11S-like and variant forms of V1 sequences in various proportions early after infection, with a median of 23.75% of E11S-type sequences. In contrast, among animals that were immunized but became

TABLE 4. Sequence analysis of the V1 hypervariable region of the challenge viruses clone E11S and uncloned SIVmne Virus

Translated V1 amino acid sequence

% abundance

E11S

TMKCNKSETDKWGLTKSSTTTAPTAIPT-KAEAIKVVNENSPCINHD

100

SIVmne

............................-.................. ........................TPKPTTTKK.E......T.V...

85 15

626

POLACINO ET AL.

J. VIROL.

TABLE 5. Analysis of the V1 hypervariable region of the SIVspecific sequences amplified from the PBMC of macaques challenged with uncloned SIVmne Animal

Challenge outcome

% of sequence of typea: E11S

Variant

SD

ne

Control Expt 1 91319 91320 91323 91324

Infected Infected Infected Infected

13.34 99.95 20.00 27.50

86.66 0.05 80.00 72.50

62.35 60.05 65.00 62.50

3 2 2 2

Expt 2 92170 92179 93032

Infected Infected Infected

0.95 3.67 95.75

99.05 96.33 4.25

60.96 64.49 64.25

4 3 2

Expt 3 91064b 91070 92168

Infected Infected Infected

99.95 96.00 5.87

0.05 4.00 94.13

60.05 62.00 62.28

2 2 3

Infected Infected Transient Protected

0.00 0.70 90.00

100.0 99.30 10.00

60.00 60.70

2 2 1

95.00 0.07

5.00 99.93

66.40 60.09

3 3

98.66 25.00

1.34 75.00

61.54

3 1

Immunized Expt 1 87201 87221 87210c 87217 Expt 2 90073 90078 90094

Protected Transient Infected

Expt 3 J90304 91250d 92163

Infected Transient Protected

a The proportion of E11S-type or variant-type sequences was determined by nucleotide sequence analysis of PCR amplified fragments cloned in M13 vectors, by PCR amplification with radiolabeled primers for quantification, or both. For every PCR analysis, DNA from cells infected with E11S or uncloned SIVmne was run as a control. Unless otherwise noted, all the samples were prepared from PBMC collected 2 weeks after challenge. b PBMC sample was collected 4 weeks after infection. The proportion of E11S-type and variant-type sequences was constant from weeks 4 through 8 in this animal. c PBMC sample was collected 4 weeks after infection, the only time when the proviral DNA was detected in this animal by nested PCR. d Data represent sequences amplified from lymph node samples collected 6 weeks after challenge, which was the only time we were able to amplify proviral DNA for this analysis. We were not able to amplify sufficient quantities of proviral DNA from the PBMC of this animal at any time for this analysis. e n, number of determinations made for each sample.

FIG. 4. Composition of V1 sequences in the uncloned SIVmne challenge virus and tissues from infected animals. (A) PCR analysis with radiolabeled primers. Radiolabeled primers specific for the E11S (E) or the variant-type (V) V1 sequence were used to amplify a 397-bp fragment from the proviral DNA from the following sources: cells infected with E11S (lanes 11 and 12) or with uncloned SIVmne (lanes 13 and 14); lymph node (LN) of an immunized animal, macaque J90304 (lanes 9 and 10), or control animals, macaques 91064, 91070, and 92168 (lanes 3 to 8), at the indicated weeks after challenge with uncloned SIVmne. All DNA samples used for analysis contained at least 50 proviral copies per reaction. (B) Heteroduplex mobility analysis. Proviral sequences present in cells infected with E11S or uncloned SIVmne and the PBMC of infected animals were analyzed after PCR amplification of the V1 to V2 region with nested sets of primers as described in Materials and Methods. The results for PBMC obtained 2 weeks after challenge are shown. PCR-amplified fragments from each sample were annealed for the formation of heteroduplexes, which were resolved by gel electrophoresis as described in the text.

persistently infected after challenge (macaques 87201, 87221, 90094, and J90304), the median percentage of E11S-type sequences was 0.39% (p 5 0.1), indicating a strong trend toward a statistically significant difference between these two groups. There was also a significantly greater proportion of animals with predominantly variant-type sequences in the immunized group than in the controls. Using the upper limit of a .99.5% confidence interval for the controls as the cutoff, we observed that 3 of 4 immunized macaques, versus 1 of 10 control animals, had predominantly (.99%) variant-type sequences (P 5 0.04). We also examined lymph node biopsy samples collected from an immunized animal (macaque J90304) 6 weeks postchallenge and from three control animals (macaques 91064, 91070, and 92168) 8 weeks postchallenge. Similar proportions of E11S- and variant-type sequences were found in the lymph node and concurrent PBMC samples from each animal examined (Fig. 4 and data not shown). Vaccine failure in gp160immunized animals therefore appears to be associated preferentially with breakthrough infection or outgrowth by varianttype viruses. Such a preference was not apparent in animals that showed only partial protection. Of the three transiently virus-positive animals, two (macaques 87210 and 90078) had mostly E11S-type sequences and one (macaque 91250) had a mixture of E11S and variant types. It should be noted that

VOL. 73, 1999

PROTECTION BY SIVmne gp160 VACCINES

627

FIG. 5. Peripheral blood CD41 T-lymphocyte numbers in immunized (A and C) and control (B and D) macaques following challenge with SIVmne E11S (A and B) or uncloned SIVmne (C and D). Animals sacrificed because of AIDS are labeled A; animals euthanized at the end of the experimentation period are labeled E; and animals that died of causes unrelated to AIDS are labeled U. The last datum point for each animal represents the time of death or termination of the experiment (euthanized, alive or rechallenged).

these animals had a significantly reduced viral load and duration of detectable viruses compared with nonimmunized controls (Fig. 1), indicating the presence of immune suppression, albeit only partially effective. The high percentage of E11S virus found in two of the three “transiently” virus-positive animals perhaps reflects this incomplete suppression. However, the low viral load and the transient nature of detectable viruses in this group preclude a direct comparison with the other animals in this study. Clinical outcome of challenge. Infected animals were monitored for up to 5 years after challenge to determine the clinical outcome of infection and the effects of immunization. The animals were monitored periodically for lymphocyte subsets, hematology, blood chemistry, body weight, opportunistic infections, and proliferative diseases. Figure 5 summarizes their peripheral blood CD41 cell levels and survival after challenge. Euthanasia was performed either because the infection progressed to cause AIDS or because the experiment was terminated. A few animals died of reasons unrelated to AIDS. Histopathological examinations were performed upon necropsy. The results in Fig. 5 demonstrate the pathogenic potentials of both E11S and uncloned SIVmne infections in M. fascicularis. Infection with the uncloned virus resulted in a more rapid clinical course than did infection with E11S. Sixty percent of the animals infected with the uncloned virus (6 of 10) were euthanized because of AIDS between 0.5 and 3 years after challenge. Three of these animals developed CD41 cell depletion within 10 months (Fig. 5D). During the same period, a

similar percentage of E11S-infected animals were also euthanized because of AIDS. However, four of five of these animals survived longer than 2 years, and none showed an appreciable decline in CD41 cell counts within the first 15 months (Fig. 5B). The median CD41 cell count at 1 year after infection was 2,082 (n 5 10; range, 375 to 3,000) and 864 (n 5 9; range, 162 to 1,547) for E11S- and uncloned SIVmne-infected animals, respectively (P 5 0.02). Among animals infected with the uncloned virus, there was no significant difference between the immunized and the control animals (Fig. 5C and D) in the proportion that required euthanasia due to AIDS (2 of 10 and 6 of 10, respectively; P 5 0.2) or in the median survival time among those that developed AIDS (78.5 and 90.5 weeks, respectively; P 5 0.6). Similarly, there were no statistically significant differences in these parameters between immunized and control animals infected with E11S (Fig. 5A and B). All immunized animals that were completely protected against virus challenge showed no sign of infection throughout the study period (10 to 28 months for animals used for rechallenge and up to 5 years for the rest) (Table 2). For animals that were transiently virus positive following challenge, the clinical outcome was variable. Two of five such animals (one of two challenged with E11S and one of three challenged with the uncloned virus) had only transient and low viral load in the peripheral blood early after infection. Viral sequences were detectable in the lymph nodes only after the acute phase of infection (Fig. 6 and data not shown). However, both animals eventually developed high levels of virus and increasing titers

628

POLACINO ET AL.

J. VIROL.

of anti-SIV antibodies (Fig. 3 and 6 and data not shown). One of these two animals (macaque 91272) was euthanized due to AIDS approximately 2 years after challenge. DISCUSSION We confirmed that immunization with recombinant SIVmne gp160 vaccines in a “prime-and-boost” regimen is highly effective against an intravenous challenge by the pathogenic homologous virus clone E11S. We also achieved complete protection against the uncloned SIVmne, which has greater genetic complexity and pathogenicity than the E11S clone, in about onethird of the immunized animals. However, protection against the uncloned virus was only partial in some animals and not apparent in others, indicating the potential limitation of similar vaccine strategies based solely on envelope antigens of a single genotype. Our results thus provide further insight into the apparently discordant observations concerning the efficacy of the primeand-boost approach with envelope-based vaccines reported in a number of primate lentivirus models (16, 19, 25, 33, 34, 47, 48). The protective efficacy of a given vaccine approach depends not only on the quantity and quality of the immune responses generated by the vaccine, but also on the biological properties and the genetic complexity of the challenge virus. Failure to achieve protective immunity with similar prime-andboost immunization protocols against SIVmac251 may be due in part to the highly virulent nature of the challenge virus, which often induces AIDS and death in monkeys within a year (5, 19). Recent data indicate that monkeys infected with SIVmac251 have a high plasma viral load, usually with peak values of .108 and steady-state values of 106 to 107 (5, 16, 21). These values are 10- to 100-fold greater than those observed in most of the SIVmne-infected animals (reference 55 and data not shown) or HIV-1-infected typical progressors (44, 45). The use of a highly virulent challenge virus such as SIVmac251 may therefore underestimate the efficacy of candidate vaccines that are capable of protecting against less virulent viruses. On the other hand, the SIVmne challenge virus appears to have only limited genetic complexity. Immunity generated by molecularly cloned vaccines may be more effective in controlling infection by a few closely related viruses than that by a “swarm,” especially if it contains highly replicative and virulent viruses. However, it remains an open question whether results from any of these models will be predictive of the relative efficacy of comparable vaccine strategies against HIV-1 infection in humans. Such a question can be answered only with efficacy data from clinical trials. Despite considerable efforts, correlates of protection in the SIV model remain elusive. Protective immunity elicited by whole killed SIV vaccines has been attributed to immune responses against cellular antigens (2, 3, 41, 53). Results from our studies indicate that cross-reactive immune responses to cellular antigens did not play an important role in protection by the recombinant gp160 vaccines, because protection was observed against viruses grown on macaque PBMC as well as those grown on human T-cell lines. Among the SIV-specific responses examined, we were unable to identify any correlate of protection. Neither total antibody response (as measured by ELISA) nor neutralizing antibodies (including those against the homologous challenge viruses, cloned or uncloned) correlate with protection. In a subset of immunized animals examined for SIV-specific CTL responses, none showed any detectable level of cytolytic activity prior to challenge (37, 37a). It is possible that protection is mediated either through a combi-

FIG. 6. Analysis of an immunized animal that was transiently virus positive early after challenge with SIVmne E11S. (Top) Viral load in plasma and CD41 T-lymphocyte counts in peripheral blood. (Bottom) Proviral load in the PBMC and SIV-specific antibody titers in serum. Detection of proviral DNA in lymph nodes (LN DNA) and isolation of virus from peripheral blood (VIRUS) at different times after challenge are as indicated at the bottom.

nation of these mechanisms or through factors yet to be determined. Another approach to study the mechanisms of protection is to analyze viruses recovered from immunized animals after challenge infection. Although our data do not distinguish breakthrough infection from preferential amplification early after infection, they indicate that such viruses were more likely to have variant sequences in the V1 hypervariable region (i.e., different from the V1 region of the vaccine strain). If further confirmed, this observation will provide indirect evidence that immune responses against determinants within the V1 region may play an important role in protection, by either preventing or limiting infection by viruses with the homologous sequences. This notion is supported by findings that the V1 region of the SIV envelope proteins contains targets for both neutralizing antibodies and cytotoxic T lymphocytes (18, 23, 33, 36, 51). Recent studies in the SIVmne model have shown that mutations in the V1 region allow the virus to escape neutralizingantibody recognition and that such mutations are selected over the course of persistent infection in macaques (18, 49, 51). The “variant-type” V1 sequences we found in immunized but infected animals have the same canonical O-linked and N-linked glycosylation sites as those observed in neutralization escape

VOL. 73, 1999

PROTECTION BY SIVmne gp160 VACCINES

mutants and in variants generated during in vivo infection. These findings indicate an important role for neutralizing antibodies in the selection or preferential outgrowth of variant viruses in animals challenged with the uncloned virus. However, it remains to be shown if and how such responses contribute to protection. For instance, while we failed to observe a correlation between protection against the uncloned SIVmne and neutralization of the homologous virus, this does not preclude the possibility that such a correlation exists for antibodies that neutralize the variant viruses specifically. Further work is needed to determine whether the failure of the E11S-based vaccines to protect against viruses with variant V1 sequences is due to differences in these putative V1 determinants per se or to differences in their biological properties (such as infectivity and pathogenicity) that are independent of V1 (i.e., variant sequence serving only as a “signature” for such differences), or both. The finding that vaccine-induced immunity may bias the type of virus transmitted after exposure also underscores the importance of identifying the relevant viruses to protect against in natural transmission as well as developing vaccines that will elicit broadly protective immunity. In this context, it is relevant to point out that by using the same combination immunization strategy, we have been able to protect against mucosal infection by uncloned SIVmne with gp160 vaccines and against intravenous infection by the same virus with vaccines consisting of both envelope and core antigens (unpublished data). Finally, a key issue in vaccine development is how vaccine efficacy is defined. It has been recognized that “sterilizing immunity” (i.e., immunity that prevents the initial infection) may not be an easily attainable or a desirable goal (4, 39, 52). Since the correlation between disease-free survival and low viral load in plasma in HIV-1-infected individuals was demonstrated, it has been proposed that reduction of viral load may be a more realistic goal for HIV vaccine trials. This notion, while supported by some studies with nonhuman primates (5, 12, 28, 35, 42, 47), is not supported by others (19, 25). Results from our study failed to show any statistically significant difference in the clinical course in control and immunized animals after infection, perhaps due to the limited number of animals and duration of experimentation. However, we did observe that two of the five immunized macaques that showed transient viremia in the peripheral blood early after challenge infection eventually developed a high viral load, CD41 cell depletion, and AIDS within the same time frame as the controls. Findings such as these should be considered in the design of HIV-1 vaccine trials in which transient viremia and reduction of virus load are to be used as surrogate markers for vaccine efficacy. ACKNOWLEDGMENTS We thank Randy Nolte, LaRene Kuller and Tom Beck for animalrelated work; Susan Gallinger, Lynda Misher, Walter Knott, and Richard Hill for expert technical assistance; Bryan Kennedy for flow cytometry analysis, Sridhar Pennathur and Gail Sylva for providing infected cells for the preparation of immunogens; Bruce Travis and Andy Watson for advice on the PCR analyses; Stephen Kent and Phil Greenberg for providing unpublished findings; Nancy Haigwood for helpful critique; and Kate Elias and Marjorie Domenowske for manuscript preparation. This work was supported in part by NIH grants AI26503 and RR00166 and by contracts AI65302 and NCI-6S-1649. REFERENCES 1. Abimiku, A. G., G. Franchini, J. Tartaglia, K. Aldrich, M. Myagkikh, P. D. Markham, P. Chong, M. Klein, M. P. Kieny, E. Paoletti, R. C. Gallo, and M. Robert-Guroff. 1995. HIV-1 recombinant poxvirus vaccine induces crossprotection against HIV-2 challenge in rhesus macaques. Nat. Med. 1:321– 329.

629

2. Arthur, L. O., J. W. Bess, Jr., R. C. Sowder, R. E. Benveniste, D. L. Mann, J. C. Chermann, and L. E. Henderson. 1992. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258:1935–1938. 3. Arthur, L. O., J. W. Bess, Jr., R. G. Urban, J. L. Strominger, W. R. Morton, D. L. Mann, L. E. Henderson, and R. E. Benveniste. 1995. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J. Virol. 69:3117–3124. 4. Bangham, C. R., and R. E. Phillips. 1997. What is required of an HIV vaccine? Lancet 350:1617–1621. 5. Benson, J., C. Chougnet, M. Robert-Guroff, D. Montefiori, P. Markham, G. Shearer, R. C. Gallo, M. Cranage, E. Paoletti, K. Limbach, D. Venzon, J. Tartaglia, and G. Franchini. 1998. Recombinant vaccine-induced protection against highly pathogenic simian immunodeficiency virus SIVmac251 dependence on route of challenge exposure. J. Virol. 72:4170–4182. 6. Benveniste, R. E., L. O. Arthur, C. C. Tsai, R. Sowder, T. D. Copeland, L. E. Henderson, and S. Oroszlan. 1986. Isolation of a lentivirus from a macaque with lymphoma: Comparison with HTLV-III/LAV and other lentivirus. J. Virol. 60:483–490. 7. Benveniste, R. E., D. Raben, R. Hill, W. Knott, J. E. Drummond, L. O. Arthur, P. B. Jahrling, W. R. Morton, L. E. Henderson, and G. Heidecker. 1989. Molecular characterization and comparison of simian immunodeficiency virus isolates from macaques, mangabeys, and African green monkeys. J. Med. Primatol. 18:287–303. 8. Benveniste, R. E., R. W. Hill, L. J. Eron, U. M. Csaikl, W. B. Knott, L. E. Henderson, R. C. Sowder, K. Nagashima, and M. A. Gonda. 1990. Characterization of clones of HIV-1 infected HuT78 cells defective in gag gene processing and of SIV clones producing large amounts of envelope glycoprotein. J. Med. Primatol. 19:351–366. 9. Benveniste, R. E., L. Kuller, S. T. Rodman, S.-L. Hu, and W. R. Morton. 1993. Long-term protection of macaques against high-dose type D retrovirus challenge after immunization with recombinant vaccinia virus expressing envelope glycoproteins. J. Med. Primatol. 22:74–79. 10. Berman, P. W., T. J. Gregory, L. Riddle, G. R. Nakamura, M. A. Champe, J. P. Porter, F. M. Wurm, R. D. Hershberg, E. K. Cobb, and J. W. Eichberg. 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345:622–625. 11. Berman, P. W., K. K. Murthy, T. Wrin, J. C. Vennari, E. K. Cobb, D. J. Eastman, M. Champe, G. R. Nakamura, D. Davison, M. F. Powell, J. Bussiere, D. P. Francis, T. Matthews, T. J. Gregory, and J. F. Obijeski. 1996. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J. Infect. Dis. 173:52–59. 12. Biberfeld, G., R. Thorstensson, and P. Putkonen. 1996. Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2. AIDS Res. Hum. Retroviruses 12:443–446. 13. Bolmstedt, A., A. Hemming, P. Flodby, P. Berntsson, B. Travis, J. P. C. Lin, J. Ledbetter, T. Tsu, H. Wigzell, S.-L. Hu, and S. Olofsson. 1991. Effects of mutations in disulfide bonds and glycosylation sites on the processing, CD4binding and fusion activity of HIV envelope glycoproteins. J. Gen. Virol. 72:1269–1277. 14. Boyer, J. D., K. E. Ugen, B. Wang, M. Agadjanyan, L. Gilbert, M. L. Bagarazzi, M. Chattergoon, P. Frost, A. Javadian, W. V. Williams, Y. Refaeli, R. B. Ciccarelli, D. McCallus, L. Coney, and D. B. Weiner. 1997. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:526–532. 15. Bruck, C., C. Thiriart, L. Fabry, M. Francotte, P. Pala, O. Van-Opstal, J. Culp, M. Rosenberg, M. De Wilde, P. Heidt, and J. Heeney. 1994. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 12:1141–1148. 16. Buge, S. L., E. Richardson, S. Alipanah, P. Markham, S. Cheng, N. Kalyan, C. J. Miller, M. Lubeck, S. Udem, J. Eldridge, and M. Robert-Guroff. 1997. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol. 71:8531–8541. 17. Chackerian, B., W. R. Morton, and J. Overbaugh. 1994. Persistence of simian immunodeficiency virus mne variants upon transmission. J. Virol. 68:4080–4085. 18. Chackerian, B., L. M. Rudensey, and J. Overbaugh. 1997. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J. Virol. 71:7719–7727. 19. Daniel, M. D., G. P. Mazzara, M. A. Simon, P. K. Sehgal, T. Kodama, D. L. Panicali, and R. C. Desrosiers. 1994. High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res. Hum. Retroviruses 10:839– 851. 20. Delwart, E. L., H. W. Sheppard, B. D. Walker, J. Goudsmit, and J. Mullins. 1994. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assay. J. Virol. 68:6672–6683.

630

POLACINO ET AL.

21. Desrosiers, R. C., J. D. Lifson, J. S. Gibbs, S. C. Czajak, A. Y. Howe, L. O. Arthur, and P. Johnson. 1998. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72:1431–1437. 22. el-Amad, Z., K. K. Murthy, K. Higgins, E. K. Cobb, N. L. Haigwood, J. A. Levy, and K. S. Steimer. 1995. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2. AIDS 9:1313–1322. 23. Erickson, A. L., and C. M. Walker. 1994. An epitope in the V1 domain of the simian immunodeficiency virus (SIV) gp120 protein is recognized by CD81 cytotoxic T lymphocytes from an SIV-infected rhesus macaque. J. Virol. 68:2756–2759. 24. Fast, P. E., and M. C. Walker. 1993. Human trials of experimental AIDS vaccines. AIDS 7:S147–S159. 25. Giavedoni, L. D., V. Planelles, N. L. Haigwood, S. Ahmad, J. D. Kluge, M. L. Marthas, M. B. Gardner, P. A. Luciw, and T. D. Yilma. 1993. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J. Virol. 67:577–583. 26. Girard, M., M. P. Kieny, A. Pinter, F. Barre´-Sinoussi, P. Nara, H. Kolbe, K. Kusumi, A. Chaput, T. Reinhart, E. Muchmore, J. Ronco, M. Kaczoreck, E. Gomard, J. C. Gluckman, and P. Fultz. 1991. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88:542–546. 27. Heidecker, G., H. Mun ˜ oz, P. Lloyd, D. Hodge, F. W. Ruscetti, S.-L. Hu, W. R. Morton, and R. E. Benveniste. 1998. Macaques infected with cloned simian immunodeficiency virus show recurring Nef gene alterations. Virology 249:260–274. 28. Hirsch, V. M., T. R. Fuerst, G. Sutter, M. W. Carroll, L. C. Yang, S. Goldstein, M. Piatak, Jr., W. R. Elkins, W. G. Alvord, D. C. Montefiori, B. Moss, and J. D. Lifson. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:3741–3752. 29. Hu, S.-L., J. M. Zarling, J. Chinn, B. M. Travis, P. A. Moran, J. Sias, L. Kuller, W. R. Morton, G. Heidecker, and R. E. Benveniste. 1989. Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoprotein of simian type D retrovirus. Proc. Natl. Acad. Sci. USA 86:7213–7217. 30. Hu, S.-L., K. Abrams, G. N. Barber, P. Moran, J. M. Zarling, A. J. Langlois, L. Kuller, W. R. Morton, and R. E. Benveniste. 1992. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456–459. 31. Hu, S.-L., B. Travis, V. Stallard, K. Abrams, L. Misher, P. Moran, J. M. Zarling, A. J. Langlois, L. Kuller, W. R. Morton, and R. E. Benveniste. 1992. Immune responses to SIVmne envelope glycoproteins protect macaques from homologous SIV infection. AIDS Res. Hum. Retroviruses 8:1489– 1494. 32. Hu, S.-L., V. Stallard, K. Abrams, G. N. Barber, L. Kuller, A. J. Langlois, W. R. Morton, and R. E. Benveniste. 1993. Protection of vaccinia-primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160. J. Med. Primatol. 22:92– 99. 33. Hu, S.-L., N. L. Haigwood, and W. R. Morton. 1993. Non-human primate models for AIDS research, p. 293–327. In W. J. W. Morrow and N. L. Haigwood (ed.), HIV molecular organization, pathogenicity and treatment. Elsevier Science Publishers, Amsterdam, The Netherlands. 34. Hu, S.-L., J. Klaniecki, B. M. Travis, T. Wrey, S. Pennathur, D. C. Montefiori, J. L. Thompson, M. B. Agy, L. Kuller, and W. R. Morton. 1997. Immunization with HIV-1 gp160 by the “prime and boost” regimen protects macaques against SHIV HXBc2 challenge. Vaccines 97:291–298. 35. Israel, Z. R., P. F. Edmonson, D. H. Maul, S. P. O’Neil, S. P. Mossman, C. Thiriart, L. Fabryl, O. Van Opstal, C. Bruck, F. Bex, A. Burny, P. N. Fultz, J. I. Mullins, and E. A. Hoover. 1994. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J. Virol. 68:1843–1853. 36. Jurkiewicz, E., G. Hunsmann, J. Schaffner, T. Nisslein, W. Luke, and H. Petry. 1997. Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein. J. Virol. 71:9475–9481. 37. Kent, S. J., S.-L. Hu, L. Corey, W. R. Morton, and P. D. Greenberg. 1996. Detection of simian immunodeficiency virus (SIV)-specific CD81 T cells in macaques protected from SIV challenge by prior SIV subunit vaccination. J. Virol. 70:4941–4947. 37a.Kent, S. J., M. Robertson, and P. D. Greenberg. Personal communication. 38. Klaniecki, J., T. Dykers, B. Travis, R. Schmitt, M. Wain, A. Watson, P. Sridhar, J. McClure, B. Morein, J. T. Ulrich, S.-L. Hu, and J. Lewis. 1991. Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 puri-

J. VIROL. fied from simian cells infected with recombinant vaccinia virus. AIDS Res. Hum. Retroviruses 7:791–797. 39. Koff, W. C., and A. M. Schultz. 1996. Progress and challenges toward an AIDS vaccine: brother, can you spare a paradigm? J. Clin. Immunol. 16: 127–133. 40. Langlois, A. J., K. J. Weinhold, T. J. Matthews, and D. P. Bolognesi. 1991. In vitro assay for detecting neutralizing and fusion-inhibiting antibodies to SIVmac251. AIDS Res. Hum. Retroviruses 7:713–720. 41. Langlois, A. J., K. J. Weinhold, T. J. Matthews, M. L. Greenberg, and D. P. Bolognesi. 1992. Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res. Hum. Retroviruses 8:1641–1652. 42. Looney, D. J., J. McClure, S. J. Kent, A. Radaelli, G. Kraus, A. Schmidt, K. Steffy, S.-L. Hu, W. Morton, and F. Wong-Staal. 1998. A minimally replicative HIV-2 live virus vaccine protects M. nemestrina from disease after HIV-2281 challenge. Virology 242:150–160. 43. Lubeck, M. D., R. Natuk, M. Myagkikh, N. Kalyan, K. Aldrich, F. Sinangil, S. Alipanah, S. C. Murthy, P. K. Chanda, S. M. Nigida, Jr., P. D. Markham, S. Zolla-Pazner, K. Steimer, M. Wade, M. S. Reitz, Jr., L. O. Arthur, S. Mizutani, A. Davis, P. P. Hung, R. C. Gallo, J. Eichberg, and M. RobertGuroff. 1997. Long term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 3:651–658. 44. Mellors, J. W., C. R. Rinaldo, Jr., P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167–1170. 45. Mellors, J. W., A. Mun ˜ oz, J. V. Giorgi, J. B. Margolick, C. J. Tassoni, P. Gupta, L. A. Kingsley, J. A. Todd, A. J. Saah, R. Detels, J. P. Phair, and C. R. Rinaldo, Jr. 1997. Plasma viral load and CD41 lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126:946–954. 46. Montefiori, D. C., W. E. Robinson, S. S. Schuffman, and W. M. Mitchell. 1988. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26:231–235. 47. Mossman, S. P., F. Bex, P. Berglund, J. Arthos, S. P. O’Neil, D. Riley, D. H. Maul, C. Bruck, P. Momin, A. Burny, P. N. Fultz, J. I. Mullins, P. Liljestrom, and E. A. Hoover. 1996. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by gp120 subunit vaccine. J. Virol. 70:1953–1960. 48. Myagkikh, M., S. Alipanah, P. D. Markham, J. Tartaglia, E. Paoletti, R. C. Gallo, G. Franchini, and M. Robert-Guroff. 1996. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retroviruses 12:985–992. 48a.Overbaugh, J. Unpublished data. 49. Overbaugh, J., L. M. Rudensey, M. D. Papenhausen, R. E. Benveniste, and W. R. Morton. 1991. Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J. Virol. 65: 7025–7031. 50. Polacino, P. S., H. A. Liang, E. J. Firpo, and E. Clark. 1993. T-cell activation influences initial DNA synthesis of simian immunodeficiency virus in resting T lymphocytes from macaques. J. Virol. 67:7008–7016. 51. Rudensey, L., J. T. Kimata, E. M. Long, B. Chackerian, and J. Overbaugh. 1998. Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVmne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition. J. Virol. 72:209–217. 52. Schultz, A. M., and S.-L. Hu. 1993. Primate models for HIV vaccines. AIDS 7(Suppl. 1):S161–S170. 53. Stott, E. J. 1991. Anti-cell antibody in macaques. Nature 353:393. 54. Stott, E. J., and G. C. Schild. 1996. Strategies for AIDS vaccines. J. Antimicrob. Chemother. 37(Suppl. B):185–198. 55. Tsai, C.-C., P. Emau, K. Follis, T. Beck, R. E. Benveniste, N. Bischofberger, J. D. Lifson, and W. Morton. 1998. Effectiveness of postinoculation of (R)9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J. Virol. 72:4265–4273. 56. Watson, A., J. Ranchalis, B. Travis, J. McClure, W. Sutton, P. R. Johnson, S.-L. Hu, and N. L. Haigwood. 1997. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J. Virol. 71:284–290. 57. Zolla-Pazner, S., M. Lubeck, S. Xu, S. Burda, R. J. Natuk, F. Sinangil, K. Steimer, R. C. Gallo, J. W. Eichberg, T. Matthews, and M. Robert-Guroff. 1998. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J. Virol. 72:1052–1059.